Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.
| Year | ID | Type | Category | Title | Authors |
|---|
| 2023 | DMT14 | Poster | Disease-modifying therapy |
Evaluating Large Scale Proteomic Changes in Cerebrospinal Fluid (CSF) of Patients Living with Multiple Sclerosis (MS) and Treated with Tolebrutinib |
Anna S. Blazier, PhD1, Gregory Wirak, PhD1, Pavithra Krishnaswami, MSc1, Mikhail Levit, PhD1, Dimitry Ofengheim, PhD1, Timothy J. Turner, PhD1, Steven Jacobson, PhD2 and Daniel S. Reich, MD, PhD2, (1)Sanofi, Cambridge, MA, (2)National Institute of Neurological Disorders and Stroke, Bethesda, MD |
| 2023 | DMT18 | Poster | Disease-modifying therapy |
Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial |
Anthony Traboulsee, MD1, Robert J. Fox, MD2, Douglas L. Arnold, MD3, Sana Syed, MD, MPH4, Larry Orogun, MD, MSc4, Deborah Dukovic, MS5, Timothy J. Turner, PhD4, Daniel S. Reich, MD, PhD6 and Jiwon Oh, MD, PhD7, (1)University of British Columbia, Vancouver, BC, Canada, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (3)NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (4)Sanofi, Cambridge, MA, (5)Sanofi, Bridgewater, NJ, (6)National Institute of Neurological Disorders and Stroke, Bethesda, MD, (7)St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada |
| 2023 | DMT19 | Poster | Disease-modifying therapy |
MRI Outcomes from the Long-Term Safety Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 2-Year Results |
Daniel S. Reich, MD, PhD1, Anthony Traboulsee, MD2, Sana Syed, MD, MPH3, Zhixing Xu, PhD4, Timothy J. Turner, PhD3 and Douglas L. Arnold, MD5,6, (1)National Institute of Neurological Disorders and Stroke, Bethesda, MD, (2)University of British Columbia, Vancouver, BC, Canada, (3)Sanofi, Cambridge, MA, (4)Sanofi, Bridgewater, NJ, (5)NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (6)NeuroRx Research, Montreal, QC, Canada |
| 2023 | DMT36 | Poster | Disease-modifying therapy |
Safety and Clinical Efficacy Outcomes from Long-Term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 2.5-Year Data |
Jiwon Oh, MD, PhD1, Sana Syed, MD, MPH2, Tong Li, PhD3, Naji Salloum, MD2, Timothy J. Turner, PhD2 and Robert J. Fox, MD4, (1)St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, (2)Sanofi, Cambridge, MA, (3)Sanofi, Bridgewater, NJ, (4)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH |
| 2023 | DMT57 | Poster | Disease-modifying therapy |
MRI, Efficacy, and Safety of Tolebrutinib in Participants with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-Term Safety (LTS) Study |
Robert J. Fox, MD1, Jiwon Oh, MD, PhD2, Douglas L. Arnold, MD3,4, Sana Syed, MD, MPH5, Zhixing Xu, PhD6, Timothy J. Turner, PhD5, Anthony Traboulsee, MD7 and Daniel S. Reich, MD, PhD8, (1)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (2)St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, (3)NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (4)NeuroRx Research, Montreal, QC, Canada, (5)Sanofi, Cambridge, MA, (6)Sanofi, Bridgewater, NJ, (7)University of British Columbia, Vancouver, BC, Canada, (8)National Institute of Neurological Disorders and Stroke, Bethesda, MD |
| 2023 | DMT66 | Poster | Disease-modifying therapy |
Comparative Central Nervous System (CNS) Pharmacology of Tolebrutinib Versus Other Bruton’s Tyrosine Kinase (BTK) Inhibitor Candidates for Treating Multiple Sclerosis |
Timothy J. Turner, PhD1, Olivier Nicolas, PhD, PharmD2, Priscilla Brun, MSc2, Dimitry Ofengheim, PhD1 and Ross C. Gruber, PhD3, (1)Sanofi, Cambridge, MA, (2)Sanofi, Montpelier, France, (3)Sanofi, Framingham, MA |